We are the European infrastructure for translational medicine
THE VISION & MISSION OF EATRIS
Our vision is to make the translation of scientific discoveries into medical products more effective to improve human health and quality of life. Our mission is to support researchers in developing their biomedical discoveries into novel translational tools and interventions for better health outcomes for society.
WHAT IS EATRIS?
EATRIS is the European infrastructure for translational medicine. We bring together resources and services for research communities to translate scientific discoveries into benefits for patients. EATRIS is what is known as an ‘ERIC’, which is a non-profit European Research Infrastructure Consortium. This specific legal form is designed to facilitate the joint establishment and operation of research infrastructures of European interest.
‘EATRIS’ has been the acronym of the European Advanced Translational Research Infrastructure in Medicine since the formation of the organisation in 2007. In November 2013, EATRIS became the first biomedical science infrastructure to receive European Research Infrastructure Consortium status, established by the European Commission.
WHAT DOES EATRIS DO?
EATRIS provides access to a vast array of pre-clinical and clinical expertise and facilities that are available within 144+ top-tier academic centres across Europe. We focus on improving and optimising preclinical and early clinical development of drugs, vaccines and diagnostics. Solutions are developed in the fields of advanced therapy medicinal products, imaging and tracing, small molecules, vaccines and biomarkers.
Our research infrastructure offers a broad range of research services for both academia and industry across various research fields. In addition, we work with public funding agencies, charities and policy makers with tailored actions to help improve the translational research and innovation ecosystem. We also provide regulatory services, training and education and mentoring. Find out more about our services here.
EATRIS focuses on pre-clinical and early clinical development of drugs, vaccines and diagnostics. Solutions are developed in the fields of advanced therapy medicinal products, imaging and tracing, small molecules, vaccines and biomarkers.
The wide-ranging services portfolio focuses on supporting early decision-making and de-risking of projects.
Examples include validation and development of in vitro and in vivo biomarkers for patient stratification, molecular imaging tracers for drug development programmes, GMP manufacturing of cellular therapy products, patient-derived xenograft models, and many more highly specialised capabilities.
Translational research is a highly multi-disciplinary and complex undertaking. As a consequence, a major challenge in developing new innovations is understanding what steps need to be taken, and what expertise and technologies are suitable to perform these steps. Researchers in need of specialised support can approach EATRIS to provide guidance in the steps to be taken, by means of clinical, biological and technological expertise available within the infrastructure. Subsequently, EATRIS will match the need with the capabilities within the infrastructure. In this way, EATRIS facilitates collaboration among academics, physicians, and developers.
EATRIS helps you de-risk and add value to your drug, vaccine or diagnostic development programme.
We do this by providing fast, tailored access to cutting-edge enabling technologies in translational research.
EATRIS Annual Report 2021
Read the EATRIS Annual Report 2021 here
Meet the team
View the vacancies in our network
Our Strategic Plan 2019-2022
Find out more about our strategic plan
EATRIS' contribution to research findings